Khan Abdullah Mohammad
Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
J Pers Med. 2022 Apr 22;12(5):676. doi: 10.3390/jpm12050676.
Waldenström's macroglobulinemia (WM) remains an incurable malignancy. However, a number of treatment options exist for patients with WM, including alkylating agents, anti-CD20 monoclonal antibodies, and small molecule inhibitors such as proteasome inhibitors and Bruton tyrosine kinase inhibitors (BTKi). The focus of this review is to highlight the role of BTKi in the management of WM. The first BTKi to receive US Food and Drug Administration approval for WM was ibrutinib. Ibrutinib has been extensively studied in both treatment-naïve WM patients and in those with relapsed/refractory disease. The next BTKi approved for use was zanubrutinib, and prospective data for acalabrutinib and tirabrutinib have also recently been published. Efficacy data for BTKi will be discussed, as well as the differences in their adverse event profiles.
华氏巨球蛋白血症（WM）仍然是一种无法治愈的恶性肿瘤。然而，对于WM患者有多种治疗选择，包括烷化剂、抗CD20单克隆抗体以及小分子抑制剂，如蛋白酶体抑制剂和布鲁顿酪氨酸激酶抑制剂（BTKi）。本综述的重点是强调BTKi在WM治疗中的作用。首个获得美国食品药品监督管理局批准用于WM的BTKi是伊布替尼。伊布替尼已在初治WM患者和复发/难治性疾病患者中进行了广泛研究。接下来获批使用的BTKi是泽布替尼，最近也公布了阿卡替尼和替拉布替尼的前瞻性数据。将讨论BTKi的疗效数据以及它们不良事件谱的差异。
